The National Institutes of Health and guidance for reporting preclinical research
| dc.contributor.author | Moher, David | |
| dc.contributor.author | Avey, Marc | |
| dc.contributor.author | Antes, Gerd | |
| dc.contributor.author | Altman, Douglas G | |
| dc.date.accessioned | 2015-11-23T15:41:27Z | |
| dc.date.available | 2015-11-23T15:41:27Z | |
| dc.date.issued | 2015-02-17 | |
| dc.date.updated | 2015-11-19T13:06:16Z | |
| dc.description.abstract | Abstract The quality of reporting clinical and preclinical research is not optimal. Reporting guidelines can help make reports of research more complete and transparent, thus increasing their value and making them more useful to all readers. Getting reporting guidelines into practice is complex and expensive, and involves several stakeholders, including prospective authors, peer reviewers, journal editors, guideline developers, and implementation scientists. Working together will help ensure their maximum uptake and penetration. We are all responsible for helping to ensure that all research is reported so completely that it is of value to everybody. Please see related article: http://dx.doi.org/10.1186/s12916-015-0266-y | |
| dc.identifier.citation | BMC Medicine. 2015 Feb 17;13(1):34 | |
| dc.identifier.uri | http://dx.doi.org/10.1186/s12916-015-0284-9 | |
| dc.identifier.uri | http://hdl.handle.net/10393/33304 | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | Moher et al.; licensee BioMed Central. | |
| dc.title | The National Institutes of Health and guidance for reporting preclinical research | |
| dc.type | Journal Article |
